Lisa Glass
Payments from drug & device makers
Across 78 payments — averaging $17.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$264
- Novo Nordisk$254
- Lilly USA, LLC$207
- Amgen$144
- AbbVie$114
- Exact Sciences$75
- plus $316 from 13 others
What the payments were for
- Food & beverage$1,375100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 16 | $264 |
| Novo Nordisk | 13 | $254 |
| Lilly USA, LLC | 11 | $207 |
| Amgen | 8 | $144 |
| AbbVie | 6 | $114 |
| Exact Sciences | 4 | $75 |
| Cranial Technologies, Inc | 5 | $72 |
| Johnson & Johnson | 3 | $40 |
| Sanofi-aventis U.S. LLC | 2 | $31 |
| GSK | 1 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $20 |
| Aimmune Therapeutics, Inc. | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $17 |
| Merck | 1 | $16 |
| Pfizer | 1 | $16 |
| Mylan Specialty L.p. | 1 | $15 |
| Bayer | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$116
How this compares
$1,375 in reported general payments places this provider in the 75th percentile of 4,119 family providers in Arizona.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 27 | $46,449 |
| MounjaroTirzepatide | 32 | $35,523 |
| EliquisApixaban | 12 | $21,119 |
| JanuviaSitagliptin Phosphate | 11 | $10,757 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $8,659 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $6,132 |
| Advair HfaFluticasone Propion/Salmeterol | 12 | $3,855 |
| Gabapentin | 61 | $1,546 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 60 | $1,385 |
| Hydroxyzine Hcl | 24 | $923 |
| Atorvastatin Calcium | 101 | $914 |
| Levothyroxine Sodium | 104 | $704 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 22 | $643 |
| Duloxetine Hcl | 30 | $636 |
| Lisinopril | 79 | $620 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $254 | $46,44927 claims |
| Lilly USA, LLCMounjaro | $207 | $35,52332 claims |
| PfizerEliquis | $16 | $21,11912 claims |
| MerckJanuvia | $16 | $10,75711 claims |
| GSKTrelegy Ellipta | $22 | $8,65912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,119 family providers in Arizona.
Other family in Vail
- Sharon MagalonaMesa$449K
- Angela GoldenMunds Park$378K
- Kimberly HallaPhoenix$332K
- Kaitlyn LouchheimScottsdale$208K
- Rebecca McCollaumMesa$149K
- Susan SarabiaSun City West$114K
- Lindsay CarterTucson$108K
- Audrey StevensonPhoenix$83K
- Keith MorsePrescott$83K
- Celeste FineGilbert$82K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.